You are here: Industry Insights > AZD1222

News List

AstraZeneca COVID-19 vaccine shows 90 per cent efficacy expresspharma
November 24, 2020
AZD1222, given as a half dose, followed by a full dose at least one month apart, showed vaccine efficacy of 90 per cent while it showed 62 per cent efficacy when given as two full doses at least one month apart.
Australia to initiate manufacturing of vaccine candidate for Covid-19 pharmaceutical-technology
November 10, 2020
Australia is planning to commence the manufacturing of Covid-19 vaccine candidate, AZD1222, at biotech firm CSL’s advanced manufacturing facility in Broadmeadows, Victoria.
Clinical trials to study AstraZeneca’s COVID-19 vaccine resume globally europeanpharmaceuticalreview
October 29, 2020
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have resumed across the world after confirmation it is safe to do so.
AstraZeneca resumes US phase III COVID-19 vaccine trial pharmatimes
October 29, 2020
AstraZeneca has resumed all clinical trials of its coronavirus vaccine candidate after the Food and Drug Administration (FDA) authorised the restart in the US.
AstraZeneca gets FDA approval to restart Phase III Covid-19 vaccine trial pharmaceutical-technology
October 28, 2020
The US Food and Drug Administration (FDA) has authorised the restart of Phase III clinical trial of AstraZeneca and Oxford University’s Covid-19 vaccine candidate, AZD1222, in the country.
COVID-19 Vaccine Trial Resumed in Japan americanpharmaceuticalreview
October 10, 2020
The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
Statement on AstraZeneca Oxford SARS-CoV-2 Vaccine, AZD1222, COVID-19 Vaccine Trials Temporary Pause drugs.com
September 23, 2020
As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222...
AMRI to Provide Sterile Fill/Finish Mfg. for AstraZeneca’s COVID-19 Vax contractpharma
September 17, 2020
To supply the vaccine candidate AZD1222 from AMRI’s drug product manufacturing facility in Albuquerque, NM.
COVID-19 Vaccine Trials Resume in UK americanpharmaceuticalreview
September 16, 2020
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Clinical trial for AstraZeneca Oxford COVID-19 vaccine candidate to resume europeanpharmaceuticalreview
September 15, 2020
After the clinical trial for AZD1222 was halted last week, the studies for AstraZeneca’s COVID-19 vaccine candidate will now resume.

Previous page 1 2 3 4 Next page